title: [Clinical evaluation of transcatheter arterial chemolipiodolization of miriplatin for multiple hepatocellular carcinoma].
abstract: The safety and efficacy of miriplatin-lipiodol suspension were investigated in 174 patients with hepatocellular carcinoma(HCC). We assessed 29 patients who underwent transarterial chemoembolization(TACE)for whole-liver multinodular HCC(mHCC), compared with 145 patients who underwent TACE for non-multinodular HCC(n-mHCC)as the controls. In the mHCC group, a treatment effect(TE)of 4 was obtained in 0%, TE3 in 38%, TE2 in 31%, and TE1 in 31%. In the n-mHCC group, TE4 was obtained in 24%, TE3 in 40%, TE2 in 32%, and TE1 in 4%. Efficacy was significantly higher in the mHCC group. In the mHCC group, Grade 3 adverse events(fever, elevated alanine aminotransferase, and thrombocytopenia)occurred in 4 patients(13. 7%). In the n-mHCC group, Grade 3 adverse events(ascites, elevated serum transaminase, and cytopenia)occurred in 33 patients(22. 7%). There was no significant difference in the change of Child-Pugh scores over time in 6 patients who underwent repetitive TACE for mHCC. In conclusion, TACE for whole-liver mHCC is generally safe, but its short-term therapeutic effects were not satisfactory. Variation in the TACE protocol using miriplatin, such as repetitive administration of miriplatin and a reduction in the treatment interval, can be alternative treatment choices for patients with whole-liver mHCC.
authors.affiliation: Dept. of Gastroenterology, Maebashi Red Cross Hospital, Japan.
authors.forename: Hirotaka
authors.initials: H
authors.lastname: Arai
authors.forename: Takeshi
authors.initials: T
authors.lastname: Kobayashi
authors.forename: Keisuke
authors.initials: K
authors.lastname: Izuka
authors.forename: Takashi
authors.initials: T
authors.lastname: Ueno
authors.forename: Kazuyo
authors.initials: K
authors.lastname: Mori
authors.forename: Daichi
authors.initials: D
authors.lastname: Takizawa
authors.forename: Mitsuo
authors.initials: M
authors.lastname: Toyoda
authors.forename: Hisashi
authors.initials: H
authors.lastname: Takayama
authors.forename: Takehiko
authors.initials: T
authors.lastname: Abe
mesh_terms: D000368:Aged; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy* / Q000473:pathology; D002404:Catheterization; D005260:Female; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D060787:Neoplasm Grading; D009367:Neoplasm Staging; D009944:Organoplatinum Compounds / Q000008:administration & dosage* / Q000009:adverse effects
chemical_list: D009944:Organoplatinum Compounds; C406530:miriplatin